Moderna, Inc. (NASDAQ:MRNA) today announced that it has received approval from the Ministry of Health, Labour and Welfare (MHLW) in Japan for a partial change application for an updated formulation…
mRNA-1283 induced a more robust immune response compared to Spikevax® COVID-19 vaccine, mRNA-1273.222 Next-generation mRNA vaccine design offers the potential of longer shelf life and storage advantages, and paves the…
The Enterprise Solutions Hub in the Philippines will support the Asia Pacific region and complements Moderna’s Enterprise Solutions Hubs in Warsaw, Poland, and Atlanta, U.S. The Philippines was selected due…
Announcement follows recent authorization of the Company’s mRNA COVID-19 vaccine in Argentina, Canada, Israel, the US, and Taiwan for active immunization to prevent COVID-19 caused by SARS-CoV-2 in children aged…
